Enzymatica AB (publ) (FRA:EN9)

Market Cap	45.39M +46.9%
Revenue (ttm)	4.77M +19.2%
Net Income	-4.90M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.1485
Previous Close	0.1530
Day's Range	0.1485 - 0.1485
52-Week Range	0.0886 - 0.4240
Beta	n/a
RSI	56.99
Earnings Date	Feb 18, 2026

About Enzymatica AB

Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company’s product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2007
• Employees: 21
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EN9

Financial Performance

In 2024, Enzymatica AB's revenue was 45.58 million, a decrease of -10.47% compared to the previous year's 50.90 million. Losses were -53.18 million, 6.94% more than in 2023.

Financial numbers in SEK